CILOSTAZOL (cilostazol) by Teva is phosphodiesterase 3 inhibitors [moa]. Approved for phosphodiesterase 3 inhibitor [epc]. First approved in 2004.
Drug data last refreshed 19h ago
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 3 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers
Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers
Worked on CILOSTAZOL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.